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and medications were taken from official sources and an institution of national 
reference of oncology services. The safety and effectiveness data were taken from 
the literature and two Colombian cohorts (one retrospective and one prospective) 
with patients older than 15 years. The unit of outcome was the proportion of deaths 
averted. The incremental cost effectiveness ratio (ICER) was estimated, univari-
ate sensitivity and probabilistic analysis were performed. Results: Model results 
indicate that under the scenario of a clinical trial not using factor was a dominated 
alternative (ICER of - 61,753,681 COP per death averted). In contrast, using data from 
the Colombian cohorts, factor was dominated strategy (ICER of - 141,421,622 COP 
for retrospective cohort and prospective cohort -215,449,438 COP). The variable that 
most impacted the outcome was the incidence of febrile neutropenia (12% for the 
clinical trial, 60% retrospective cohort and 83% prospective cohort). The results were 
robust to the probabilistic sensitivity analysis. With the data from the clinical trial 
in 94% of cases using factor was cost effective, while in the Colombian data in 84% 
and 72% of cases (retrospective and prospective cohort respectively) was not cost 
effective to use factor. ConClusions:: With Colombian information the prophy-
lactic use of the factor under chemotherapeutic induction in adults with ALL turns 
out to be not cost-effective. The gap in the results suggests a careful extrapolation 
of information from clinical trials (ideal world) to develop economic evaluations in 
Colombia, and its impact on decision making.
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Cost-EffECtivENEss of full-fiEld digital MaMMograPhy vErsus 
sCrEEN-filM MaMMograPhy iN BrEast CaNCEr sCrEENiNg
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objeCtives: Analyze the cost-effectiveness of full-field digital mammography (DM) 
compared to the screen-film mammography (SFM) among different age groups of 
Mexican women. Methods: A cost-effective study was developed - from the public 
sector perspective- to estimate the cost per cancer detected by DM vs. SFM in the 
following age groups: 40-49, 50-59 and 60-69 years old. Additional costs and effects 
were estimated by comparing DM against SFM and expressed as incremental cost-
effectiveness ratio (ICER). The outcome was the number of detected cases. Staff 
wages and tests cost (mammography, ultrasound and biopsy) were included. An 
univariate sensitivity analysis was carried out with key variables. Results: DM is 
more expensive and more effective than SFM for breast cancer detection. Using DM 
for 50-59 age group is not cost- effective since it detects fewer cases at a higher cost. 
In the 40-49 age group, the ICER for DM was $318,828 per additional case detected, 
while in the 60-69 the ICER for DM was $255,636. The ICER was sensitive to the lower 
cost of DM. ConClusions: For some age groups, DM is more effective than SFM; 
however, DM cost limits its use in a screening program. Evidence shows, SFM still 
has advantages in detecting breast cancer at an affordable cost. Further research 
taking into consideration social, organizational and staff training issues is important
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ParaMEtEr valuEs assoCiatEd with thE dEvEloPMENt of a gloBal 
ECoNoMiC ModEl to valuE CoMPaNioN diagNostiCs iN advaNCEd/
MEtastatiC CaNCEr trEatMENt
Lachaine J., Mathurin K., Beauchemin C.
University of Montreal, Montreal, QC, Canada
objeCtives: Many targeted anticancer drugs under development will be used with a 
companion diagnostic. The objective of this study was to define parameter values that 
will be included in a global model estimating the cost-effectiveness of a companion 
diagnostic in advanced/metastatic cancer treatment. Methods: As the model will 
be generic to allow its use in the most common cancers in Canada (breast, prostate, 
lung, colorectal, bladder, cervical, non-Hodgkin’s lymphoma), specific parameters 
for each cancer of interest (including health state utilities and costs associated with 
cancer management) were considered. Consequently, a literature review was con-
ducted using electronic databases from January 2000 until September 2013 to extract 
these parameters in economic models in advanced/metastatic cancer available. Cross-
references studies and governmental publications were also consulted. Canadian 
costs and disutilities associated with any grade 3-4 treatment-related adverse events 
(AEs) were also obtained. Results: Lung cancer was associated with the highest 
inpatient cost ($CAN19,875/stay of 9.9 days on average), while patients with prostate 
cancer incurred the highest cost associated with emergency visits ($CAN721.55/case). 
Costs associated with end-of-life care were similar among cancer types, with an aver-
age cost of $CAN31,081/case and 152 days of end-of-life care. Thirty-nine AEs were 
retrieved. Costs associated with management of AEs were up to $CAN71,967/case 
(development of secondary malign neoplasm), with an average cost of $CAN7,717/
event. Disutilities associated with the incidence of AEs were up to 0.465 (hip fracture), 
with an average utility loss of 0.135. Lung cancer presented the worst health state 
utility values (0.611 in pre-progression and 0.441 in progression). ConClusions: 
Although the model structure and key elements required to assess the cost-effec-
tiveness of a companion diagnostic can be generalized to different cancer types, this 
study suggests that parameter values should be specific to the cancer of interest.
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objeCtives: Screening of all patients diagnosed with colorectal cancer for Lynch 
syndrome using a staged testing procedure is currently recommended by Evaluation 
of Genomic Applications in Practice and Prevention (EGAPP) guidelines. Next gen-
eration sequencing (NGS) is a disruptive technology that likely offers improved 
outcomes, but its value is uncertain. The goal of this study was to evaluate the 
cost effectiveness of NGS vs. tumor tissue testing for universal testing of patients 
with colorectal cancer (CRC) to detect relatives with Lynch syndrome. Methods: 
adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) was 
calculated. As Japanese Ministry of Health, Labour and Welfare has not yet approved 
abiraterone due to the delay in development, the drug cost was estimated based 
on prices in four other countries. In the present study, resource use was estimated 
using a Japanese claim data set with 2000 claim data of prostate cancer patients 
from January 2005 to March 2013. Both cost and outcomes were discounted at a 
2% annual rate. Results: The result of this study revealed that abiraterone plus 
prednisolone indicated higher QALYs than prednisolone alone. In the base-case 
analysis, ICER for abiraterone plus prednisolone exceeded JPY 17 million (roughly 
EUR 120,000) per QALY gained. One-way sensitivity analysis for the price of abira-
terone influenced ICER (JYP 12.5 - 21 million). ConClusions: The present study 
suggested that the ICER is more than JPY 10 million. Further deliberate discussion 
on cost-effectiveness of abiraterone in Japan is needed to consider the Japanese 
price and clinical outcomes.
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usE of Psa sloPE to guidE adjuvaNt radiothEraPy iN Post-
ProstatECtoMy ProstatE CaNCEr has PotENtial to BE Cost EffECtivE
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objeCtives: NADiA ProsVue is a prognostic system developed to identify men at 
lower risk for clinical recurrence of prostate cancer following radical prostatec-
tomy, as indicated by a prostate-specific antigen (PSA) slope < = 2 pg/mL/month. 
We evaluated the potential cost-effectiveness of using the prognostic system to 
guide adjuvant radiotherapy (ART) in men considered to be at intermediate- or 
high-risk for recurrence based on the CAPRA-S nomogram. Methods: We devel-
oped a decision analytic model consisting of a decision tree to stratify men into 
risk groups and a state transition model to generate long-term costs and outcomes. 
We derived model parameters using patient-level data from the product’s 510(k) 
registration study, the medical literature and other sources. We conducted probabil-
istic, one-way and two-way sensitivity analyses to examine the cost-effectiveness 
of the system (i.e. with PSA slope findings) versus standard care (i.e. without PSA 
slope findings). Results: The cost-effectiveness of a PSA slope-guided strategy 
varied widely due to small differences in QALYs at 10 years. Assuming that 20% of 
men in the intermediate-risk CAPRA-S group receive ART with standard care, the 
incremental cost-effectiveness ratio (ICER) is less than $50,000 per QALY when use 
of ART is less than 8.2% among men with PSA slopes < = 2 pg/mL/month. Assuming 
that 40% in the high-risk CAPRA-S group receive ART with standard care, ART would 
have to decrease to at least 11.5% among men with PSA slopes < = 2 pg/mL/month to 
achieve an ICER less $50,000 per QALY. ICERS were also sensitive to varying the costs 
of the prognostic system and ART, varying the benefits of salvage therapy and utility 
weights for ART toxicities. ConClusions: The ProsVue system has the potential 
to be cost effective, but its value will be dependent on the magnitude of reduction 
in ART among men identified as having a low risk of recurrence.
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Cost-EffECtivENEss of CEtuxiMaB as first-liNE trEatMENt for 
MEtastatiC ColorECtal CaNCEr iN thE uNitEd statEs
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objeCtives: To evaluate the clinical and economic tradeoffs associated with 
FOLFIRI + either cetuximab or bevacizumab as 1st-line therapies among KRAS wild 
type (WT) metastatic colorectal cancer (mCRC) patients, through a cost-effective-
ness analysis incorporating Phase III FIRE3 clinical trial data. Methods: A deter-
ministic cost-effectiveness model was developed to project lifetime survival and 
costs of FOLFIRI used with either cetuximab or bevacizumab. A cohort of 1st-line 
patients faced risks of adverse events, progression to 2nd-line treatment, or eligibility 
for curative liver resection. Clinical trial data, published literature, and publicly avail-
able databases were used to estimate model inputs. Incremental cost-effectiveness 
ratios (ICERs) were calculated as 2013 US$ per life year (LY) and per quality-adjusted 
life year (QALY). We conducted a scenario analysis to analyze the subset of RAS WT 
patients. The impact of parameter uncertainty was also evaluated with one-way and 
probabilistic sensitivity analyses. Results: Compared with 1st-line bevacizumab 
KRAS WT patients, those treated with cetuximab gained an additional 5.7 months of 
life (42.9 vs. 37.2) at a cost of $46,301 ($280,933 vs. $234,632), for an ICER of $97,297/LY 
($122,704/QALY). The benefits of cetuximab were also greater for RAS WT patients, 
for whom the ICER was $77,380/LY ($99,636/QALY). Treatment with cetuximab would 
be cost effective 53.6% of the time, given a willingness to pay threshold of $100,000/
LY. Results were most sensitive to changes in 1st-line survival, treatment duration, 
and product acquisition costs. ConClusions: Treatment with cetuximab + FOLFIRI 
in 1st-line mCRC patients may improve health outcomes and use financial resources 
more efficiently than bevacizumab + FOLFIRI, given current societal standards. This 
information can be useful to clinicians, payers, and policy makers in making treat-
ment and resource allocation decisions for KRAS WT and RAS WT mCRC patients.
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objeCtives: To determine the cost-effectiveness of prophylactic administration 
of Filgrastim compared with no use, during the induction phase of chemother-
apy in adults with Acute Lymphoblastic Leukemia (ALL) in the Colombian con-
text. Methods: A decision tree with a time horizon of 30 days is built under the 
third-party payer perspective including only direct costs. The costs of procedures 
